The phase II randomized, non-comparative EFFORT trial reported the efficacy of adavosertib (WEE1 inhibitor) in PARP-resistant ovarian cancer with an objective response rate (ORR) of 29% in the combination adavosertib plus olaparib arm and 23% with adavosertib alone [87]. The gene discussed is WEE1; the disease is ovarian cancer.